Is Vyvanse More Effective Than Other ADHD Stimulants?
Vyvanse (lisdexamfetamine) is NOT definitively more effective than methylphenidate for treating ADHD—both stimulants have similar large effect sizes (approximately 1.0), and individual response is idiosyncratic, with about 40% of patients responding to both and 40% responding to only one. 1
Evidence-Based Treatment Algorithm
First-Line Stimulant Selection
Start with either methylphenidate OR lisdexamfetamine as first-line therapy—both are equally appropriate initial choices 2. The guidelines explicitly state that stimulants have effect sizes around 1.0, which is substantially larger than non-stimulants (effect size 0.7) 1.
However, there are important nuances:
- In the United States: Lisdexamfetamine is approved as first-line therapy 2
- In many European countries: Lisdexamfetamine is approved only as second-line therapy (after inadequate response to methylphenidate) 2
When Lisdexamfetamine Shows Advantage
If methylphenidate fails at adequate dosing and duration, switch to lisdexamfetamine as the next option—NOT to non-stimulants 2. This recommendation is based on:
- Post-hoc analysis showing lisdexamfetamine produced statistically significantly greater ADHD-RS-IV score reduction (-5.6 points) compared to OROS-methylphenidate 3
- Meta-analysis demonstrating amphetamine products (including lisdexamfetamine) have moderately greater effect sizes than methylphenidate products 4
- Higher response rates: 17.4% more patients achieved CGI-I scores of 1-2 with lisdexamfetamine versus OROS-methylphenidate (NNT=6) 3
Critical Caveats
Individual response is unpredictable—approximately 40% of patients respond to both methylphenidate and amphetamine, while 40% respond to only one 1. This means:
- You cannot predict which stimulant will work for a specific patient
- ADHD subtype does NOT predict response to a specific agent 1
- Trial of both stimulant classes may be necessary to find optimal response
Comparative Efficacy Data
Recent meta-analysis in adults showed 5:
- Lisdexamfetamine: High effect size (SMD -0.89)
- Mixed amphetamine salts: Moderate effect size (SMD -0.64)
- Methylphenidate: Moderate effect size (SMD -0.50)
However, a 2024 matching-adjusted indirect comparison found lisdexamfetamine had greater efficacy than methylphenidate but also significantly higher rates of adverse events including insomnia (12.47% difference), dry mouth (12.33% difference), and decreased appetite (20.25% difference) 6.
Safety Considerations
Lisdexamfetamine has a more favorable abuse profile due to its prodrug formulation requiring enzymatic conversion to active d-amphetamine, resulting in slow onset and long duration (approximately 12 hours) with minimal abuse potential 7, 8. This is explicitly noted in FDA labeling 9.
Both medications require monitoring of:
- Blood pressure and heart rate
- Height and weight (especially in children)
- Cardiovascular status before initiation 2
Practical Dosing Differences
Lisdexamfetamine offers once-daily dosing with 12-hour duration 2, 7, while methylphenidate formulations vary:
- 12-hour formulations
- 8-hour formulations
- Immediate-release (3-4 hours) 7
This "around-the-clock" effect may improve adherence and reduce afternoon/evening rebound symptoms 2.
Bottom Line Algorithm
- Start with methylphenidate OR lisdexamfetamine (both first-line in US; methylphenidate first-line in Europe)
- Optimize dose adequately before declaring treatment failure
- If inadequate response to methylphenidate → switch to lisdexamfetamine (NOT to non-stimulants)
- If inadequate response to lisdexamfetamine → switch to methylphenidate
- Only after trials of BOTH stimulant classes should non-stimulants be considered 2
The evidence does NOT support claiming lisdexamfetamine is universally "more effective"—rather, it may be moderately more effective on average, but individual response variability means both stimulants must be available as treatment options 1, 4.